KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Abbott Laboratories (ABT) Other Gross PP&E Adjustments (2016 - 2026)

Abbott Laboratories' Other Gross PP&E Adjustments history spans 18 years, with the latest figure at $23.1 billion for Q1 2026.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 6.53% to $23.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $23.1 billion, a 6.53% increase, with the full-year FY2025 number at -$585.0 million, down 6.95% from a year prior.
  • Other Gross PP&E Adjustments hit $23.1 billion in Q1 2026 for Abbott Laboratories, up from -$585.0 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for ABT hit a ceiling of $23.1 billion in Q1 2026 and a floor of -$605.0 million in Q4 2022.
  • Historically, Other Gross PP&E Adjustments has averaged $15.3 billion across 5 years, with a median of $19.1 billion in 2023.
  • The widest YoY moves for Other Gross PP&E Adjustments: up 47.53% in 2022, down 10.3% in 2022.
  • Tracing ABT's Other Gross PP&E Adjustments over 5 years: stood at -$605.0 million in 2022, then increased by 1.98% to -$593.0 million in 2023, then grew by 7.76% to -$547.0 million in 2024, then fell by 6.95% to -$585.0 million in 2025, then soared by 4055.04% to $23.1 billion in 2026.
  • Business Quant data shows Other Gross PP&E Adjustments for ABT at $23.1 billion in Q1 2026, -$585.0 million in Q4 2025, and $23.1 billion in Q3 2025.